// App-Quantinova.ai

: Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials

Researchers

Presenter

  • Roland Buhl

Principal Investigators

  • Franois Maltais

  • Roger Abrahams

  • Lars Grnke

  • Florian Voss

  • Dave Singh

Medical Centers

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

  • Institut universitaire de cardiologie et de pneumologie de Quebec, Quebec, QC, Canada

  • Morgantown Pulmonary Clinical Research, Morgantown, United States of America

  • Boehringer Ingelheim Corporation, Ingelheim am Rhein, Germany

  • University of Manchester, Manchester, United Kingdom

Locations

  • Germany

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Tiotropium bromide

Outcome

  • N/A

Study Design

  • Fixed Dose

Phase

  • III

Study Id's

  • NCT01431287

  • NCT02006732

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved